Articles by MD Magazine Staff

Latest Articles

CURE Highlights the Importance of Colorectal Cancer Screenings VIDEO
  |  MD Magazine Staff
Colorectal cancer has long been thought of as an older person’s disease, however, people being diagnosed are getting younger and younger. John L. Marshall, MD, a medical oncologist at Georgetown University in Washington, District of Columbia said that nearly half of his patients with colorectal cancer are under the age of 50.
Type 2 Diabetes: Improving Care in the Community
  |  MD Magazine Staff
As a conclusion to this panel discussion, moderator Peter Salgo, MD, asks experts Vivian Fonseca, MD; Robert Henry, MD; Julio Rosenstock, MD; and Carol Wysham, MD, to share their final thoughts on optimizing care for patients with type 2 diabetes mellitus in community practice.
Differentiating Among Newer Combinations in Diabetes
  |  MD Magazine Staff
Expert panelists Vivian Fonseca, MD; Robert Henry, MD; Julio Rosenstock, MD; Peter Salgo, MD; and Carol Wysham, MD, review the DUAL-1 and DUAL-2 phase III clinical trial findings in type 2 diabetes mellitus and discuss ways to differentiate among the insulin-glucagon-like-peptide 1 receptor antagonist combinations.
Switching to an Insulin-Based Combination
  |  MD Magazine Staff
In this segment, Vivian Fonseca, MD; Robert Henry, MD; Julio Rosenstock, MD; Peter Salgo, MD; and Carol Wysham, MD, provide insight on the appropriate starting dose and method of titration with the insulin-glucagon-like-peptide 1 receptor antagonist combinations in type 2 diabetes mellitus.
LixiLan Trials in Type 2 Diabetes
  |  MD Magazine Staff
Vivian Fonseca, MD; Robert Henry, MD; Julio Rosenstock, MD; Peter Salgo, MD; and Carol Wysham, MD, review the LixiLan-O and LixiLan-L trial design and findings in type 2 diabetes mellitus.
GLP-1 Receptor Antagonist Therapy in Type 2 Diabetes
  |  MD Magazine Staff
In this segment, Julio Rosenstock, MD; Peter Salgo, MD; and Carol Wysham, MD, review the differences between short- and long-acting glucagon-like-peptide 1 receptor antagonists in type 2 diabetes mellitus.
Insulin-Based Combinations in Type 2 Diabetes
  |  MD Magazine Staff
Vivian Fonseca, MD; Robert Henry, MD; Julio Rosenstock, MD; Peter Salgo, MD; and Carol Wysham, MD, explain the clinical rationale for the use of insulin in combination with a glucagon-like peptide 1 receptor antagonist in type 2 diabetes.
Early Combination Therapy in Type 2 Diabetes
  |  MD Magazine Staff
In this segment, Vivian Fonseca, MD; Robert Henry, MD; Julio Rosenstock, MD; Peter Salgo, MD; and Carol Wysham, MD, discuss the optimal way to titrate insulin therapy as well as the rationale for an intensive upfront approach in type 2 diabetes.
Preparing Patients for Insulin in Type 2 Diabetes
  |  MD Magazine Staff
Vivian Fonseca, MD; Robert Henry, MD; Julio Rosenstock, MD; Peter Salgo, MD; and Carol Wysham, MD, explain some of the barriers to initiating insulin therapy in patients with type 2 diabetes and share their best practices in overcoming them.

Most Popular

@MDMagazine

$vacMongoViewPlus$ $vAR$